BioNTech SE (BNTX)
Vaccine stocks fall following FDA resignation
Dr. Kavita Patel joins 'Fast Money' to talk the impact of FDA and HHS changes on vaccines, public health policy, and more.
Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul
Shares of U.S. drugmakers fell on Monday after reports that the Food and Drug Administration's top vaccine official was forced to resign, the most high-profile exit at the regulator as the Trump administration undertakes an overhaul of federal health agencies.
Vaccine stocks fall after key FDA official resigns in protest of RFK Jr.
Shares of vaccine makers Moderna and Novavax, along with a range of other biotech companies, fell after the resignation of key FDA official Peter Marks. Marks stepped down in protest of Health and Human Services Secretary Robert F.
Biotech stocks tumble on reports FDA's top vaccine regulator to leave
Shares of U.S. biotech companies fell as much as 10% premarket on Monday following reports that a top vaccine official at the U.S. Food and Drug Administration had resigned, fanning worries over slower reviews for breakthrough treatments.
BioNTech's Pivot Into Oncology Still Makes It A Compelling Investment
BioNTech is expanding its oncology pipeline with FixVac, iNeST, and BNT327 for individualized cancer treatments. However, note that some regulatory and legal challenges, including a Moderna patent ruling, remain pending, which poses short-term headwinds. Nevertheless, BNTX's robust balance sheet makes it cheap relative to its long-term potential. It also de-risks the company until it refocuses on oncology.
BioNTech SE (BNTX) Q4 2024 Earnings Call Transcript
BioNTech SE (NASDAQ:BNTX ) Q4 2024 Earnings Conference Call March 10, 2025 8:00 AM ET Company Participants Michael Horowicz - Director, Investor Relations Ugur Sahin - Co-Founder and Chief Executive Officer Ozlem Tureci - Co-Founder and Chief Medical Officer Jens Holstein - Chief Financial Officer Ryan Richardson - Chief Strategy Officer Conference Call Participants Daina Graybosch - Leerink Partners Akash Tewari - Jefferies Chris Shibutani - Goldman Sachs Tazeen Ahmad - Bank of America Securities Terence Flynn - Morgan Stanley Harry Gillis - Berenberg Cory Kasimov - Evercore Sadia Rahman - Wells Fargo Asthika Goonewardene - Truist Securities Yaron Werber - TD Cowen Jessica Fye - JP Morgan Operator Welcome to BioNTech's Fourth Quarter and Full-Year 2024 Earnings Call. I would like to hand the call over to Michael Horowicz, Director of Investor Relations.
BioNTech Stock Drops as Sales Outlook Disappoints
U.S.-listed shares of BioNTech (BNTX) lost ground Monday, as the COVID-19 vaccine maker's soft outlook for the year offset better-than-expected quarterly results.
BioNTech Surpasses Q4 Revenue Estimates
Biopharmaceutical company BioNTech SE (BNTX -1.85%) reported fourth-quarter and full-year 2024 earnings on Monday, March 10, that topped analysts' consensus expectations. It reported revenue of 1.19 billion euros, ahead of estimates for 1.14 billion but down nearly 43% from the prior year's quarter.
BioNTech guides for worse-than-expected 2025 revenue decline
German COVID-19 vaccine maker BioNTech on Monday said that its 2025 revenues would likely fall to between 1.7 billion euros ($1.85 billion) and 2.2 billion euros, prompting a decline in its share price.
BioNTech Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
BioNTech SE BNTX will release its fourth-quarter financial results before the opening bell on Monday, March 10.
U.S. FDA places clinical hold on BioNTech's malaria vaccine study
BioNTech said in a regulatory filing on Tuesday the U.S. Food and Drug Administration has placed a clinical hold on an early-to-mid stage trial of its malaria vaccine.
FDA Vaccine Panel Meeting To Discuss Flu Shots Reportedly Canceled
A meeting of the Food and Drug Administration's vaccine advisory committee to discuss the next season's flu vaccine has reportedly been canceled, the second such disruption of a meeting involving vaccine policy experts at the federal level since prominent vaccine skeptic Robert F. Kennedy Jr took over as the Health and Human Services secretary earlier this month.
